during progression accompanied by modulation of sFlt1. These observations were associated with GEC damage that showed altered VEGFR signaling. Importantly, EVs presented with VEGFRs and angiomodulatory microRNA. These EVs successfully integrated within GEC and modulated VEGF activity. EVs lacking both the full and soluble VEGFR-1 failed to rescue GEC from VEGF inflicted damage.
INTRODUCTION AND OBJECTIVES:
To date, there is no evidence exploring the protective effects of stem cells on minimizing ischemia reperfusion injury in a higher animal model.
METHODS: A group of 60 dogs were maintained to perform kidney injury model. Ischemia of 90 minutes were performed by open occlusion of left renal artery in 57dogs. Group I included 27 dogs that were treated with Bone marrow derived Mesenchymal Stem cells (BM-MSC) while group II (27 dogs) treated with adipose tissue derived Mesenchymal Stem cells (AT-MSC). Each group was divided into 3 subgroups (9 dogs each), according to the stem cell dose (5, 10, 15 X 10 6 in 500 ml volume) injected directly in the kidney cortex after reperfusion. 3 dogs were positive control without MSC treatment while 3 were sham-operated. All dogs were reevaluated by renogram prior to sacrifice at 2 weeks, 2 and 3 months as well as histopathology of the investigated kidney. Pro-inflammatory markers CD95 and TNF were assessed using real time PCR.
RESULTS: In group I, there was mean reduction of clearance of the investigated kidney by a mean of 78%,64% and 74% of the three used doses respectively at 2 weeks. At 3 months, these kidneys regained a mean of 84%, 92% and 72% respectively of its basal function. In group II, the reduction of clearance was much more modest with mean of 14%, 6% and 24% respectively at 2 weeks with more intense recovery of renal function by mean of 90%,100% and 76% respectively. Positive control showed more intense reduction of clearance by 90% at 2 weeks that regained 70% of basal function at 3 months. On histopathologic examination in group I, there was more significant tubular necrosis and delayed regeneration compared with group II. The histopathological insult was more pronounced in the control group with more delayed recoverability. Expressions of Pro-inflammatory markers were up regulated in both groups with higher and more sustained expression observed in group I.
CONCLUSIONS: Stem cell might protect against the ischemia reperfusion injury in canine model. AT-MSC would provide the best protective potentiality compared with BM-MSC. RESULTS: With five years of clinical follow up, a total of 11 cases experienced rejection episodes (3 DBMI patients vs. 8 controls, p ¼ 0.15). One DBMCinfused iopsy-confirmed) in the control patients. Actuarial and death-censored 5-y graft survival was significantly higher in infused patients compared with controls (p ¼ 0.01 and p ¼ 0.03, respectively). Long-term graft survival was significantly associated with pre-transplant anti-HLA antibodies (p¼ 0.01), slightly with peripheral microchimerism (p ¼ 0.09) and CD4+CD25+FoxP3+ T cells (p ¼ 0.09). Immunosuppressant dosing was lower in infused patients than controls, particularly for mycophenolate mofetil (p ¼ 0.001).
CONCLUSIONS: The current findings as well as our previous reports on these patients indicates clinical improvement in long-term graft survival of renal transplant patients resulting from low-dose DBMC infusion given without induction therapy. METHODS: Female 10-week-old Sprague-Dawley rats were used for induction of chronic IC model. Chronic IC model was induced with single intravesical instillation of protamine sulfate (0.5ml of PS, 30mg/ml) and lipopolysaccharide (0.5ml of LPS, 2.25mg/ml) for 1 month. Rats were divided into three groups (N¼5~7): non treated control group(Control), sham operation group(Sham), chronic IC receiving a single bladder submucosal injection of phosphate-buffered saline (20 mL, PBS) or chronic IC treated with CHA1 (5Â105 cells/20 mL, IV or BL(submucosa injection)). Four weeks after treatment, voiding spot was obtained using 6hr metabolic cage and analyzed with Image J program. The bladder was harvested for histologic examinations and toluidine blue staining for mast cell. All animal experiments were approved by the Institutional Animal Care and Use Committee at our institution.
RESULTS: Rats in the IV and BL group showed increased voiding frequency and decreased the spot size compared with control sham group (p<0.05). Significant improvement of voiding spot pattern in size was observed in the CHA1 treated IV and BL e532 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Saturday, May 13, 2017 
